Low expression of SHP-2 is associated with less favorable prostate cancer outcomes
| Autor: | Karin Jirström, Anders Bjartell, Pirkko Härkönen, Helena Tassidis, Anette Gjörloff Wingren, David Ulmert, Leon J. S. Brokken |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
PCA3
Biochemical recurrence Male Pathology medicine.medical_specialty Medicin och hälsovetenskap Cytoplasm Protein Tyrosine Phosphatase Non-Receptor Type 11 Biology Medical and Health Sciences Immunoenzyme Techniques Prostate cancer DU145 Prostate LNCaP medicine Tumor Cells Cultured Humans Phosphorylation Aged Neoplasm Staging Prostatectomy Tissue microarray Prostatic Neoplasms General Medicine Middle Aged medicine.disease Prognosis Survival Rate medicine.anatomical_structure Tissue Array Analysis Tissue microarray (TMA) Cancer cell Cancer research Disease Progression Stromal Cells Src homology 2 domain-containing tyrosine phosphatase-2 (SHP-2) Follow-Up Studies Signal Transduction |
| Zdroj: | Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 34(2) |
| ISSN: | 1423-0380 |
| Popis: | Src homology 2 domain-containing tyrosine phosphatase-2 (SHP-2) is an important regulator of cell signaling because of its ability to dephosphorylate receptors of growth factors as well as the cytokines and tyrosine-phosphorylated proteins associated with these receptors. In the current study, we used four different prostate cancer cell lines: PC3, DU145, LNCaP and LNCaP-IL6+. Tumor specimens from 122 patients with prostate cancer were analyzed using a tissue microarray. Our data demonstrate that all four prostate cancer cell lines express the SHP-2 protein. Additionally, low staining intensity and SHP-2 expression in the cytoplasm of cancer cells in prostate tumor specimens was inversely correlated with prostate volume (p = 0.041 and p = 0.042, respectively) whereas nuclear staining was positively correlated with extracapsular extension (p = 0.039). In our post-prostatectomy specimens, we found that patients with low SHP-2 expression had less favorable outcomes with respect to biochemical recurrence and clinical progression (p = 0.005 and p = 0.018, respectively). The loss of cytoplasmic SHP-2 expression is associated with increased growth and prostatic cancer progression. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink